Respiratory company Vapotherm provides business update in response to COVID-19 pandemic - Gilde Healthcare

Respiratory company Vapotherm provides business update in response to COVID-19 pandemic

24 maart 2020

New Hampshire (United States) – Vapotherm, Inc. (NYSE: VAPO), the Gilde Healthcare company focused on the commercialization of its proprietary Hi-VNI Technology products that are used to treat patients suffering from respiratory distress, today announced an update on their business in response to the COVID-19 pandemic.

Vapotherm’s High Velocity Nasal Insufflation (HVNI) Technology, an advanced form of High Flow Oxygen therapy1, is a first-line therapy for COVID-19 patients who are struggling to breathe. The Journal of American Medical Association (JAMA) published research showing that 19% of COVID-19 patients are in respiratory distress and need some form of support to get the oxygen they need to stay alive.2 Our hospital customers are using our technology to support COVID-19 patients in mild to moderate respiratory distress, so that they can triage their sickest patients to a limited number of ventilators.

“At Vapotherm, customers and their patients are our total focus. Despite the challenging current environment, our entire team is working to support our hospital customers as they treat COVID-19 patients suffering with respiratory distress,” said Joe Army, President and CEO of Vapotherm. “We have seen a significant increase in demand for our products in Europe and have been preparing for similar increases in the United States. We are working diligently to increase our production of Precision Flow systems and disposables for use in treating this global pandemic.”

Vapotherm has seen significant increase in demand for Vapotherm Precision Flow® systems and single-use disposables as a result of COVID-19. The Company has been working to materially increase production capacity in its facility in New Hampshire, while ensuring the safety of employees at all times. Vapotherm has increased the number of production shifts and has identified additional opportunities to further increase manufacturing capacity in an effort to keep up with growing demand. This increased production is putting pressure on our supply chain and the Company is working with policy makers and suppliers to increase availability of critical parts to support production at these higher levels.

 

About Vapotherm
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.1 million patients have been treated with Vapotherm Hi-VNI Technology. For more information, visit www.vapotherm.com.

About Hi-VNI® Technology
Hi-VNI® Technology is mask-free noninvasive ventilation for spontaneously breathing patients and a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one user-friendly tool. Hi-VNI Technology’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing $ 1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support...
25 november 2024

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
14 november 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
30 oktober 2024